

2019 Future of Autism R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/29B3981FE59EN.html>

Date: February 2019

Pages: 130

Price: US\$ 2,199.00 (Single User License)

ID: 29B3981FE59EN

Abstracts

The global demand for Autism treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Autism pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Autism pipeline companies from advancing their products into Phase 3 or Phase 4.

Autism Report Description-

The 2019 pipeline study on Autism pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Autism pipeline compounds.

The Autism pipeline guide presents information on all active drugs currently being developed for Autism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Autism

pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Autism drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Autism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Autism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Autism pipeline report includes-

An overview of Autism disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Autism pipeline

Company wise list of Autism pipeline

Mechanism of Action wise Autism pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator,

Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Autism pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Autism pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Autism pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL AUTISM PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Autism Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Autism pipeline, H1- 2019
- 3.5 Mechanism of Action wise Autism Pipeline Candidates

4 4D PHARMA PLC AUTISM PIPELINE DETAILS

- 4.1 4D Pharma PLC Business Profile
- 4.2 4D Pharma PLC Autism Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 AGENEBIO INC AUTISM PIPELINE DETAILS

- 5.1 AgeneBio Inc Business Profile
- 5.2 AgeneBio Inc Autism Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 APET HOLDING BV AUTISM PIPELINE DETAILS

- 6.1 APeT Holding BV Business Profile
- 6.2 APeT Holding BV Autism Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 AXIAL BIOTHERAPEUTICS AUTISM PIPELINE DETAILS

- 7.1 Axial Biotherapeutics Business Profile
- 7.2 Axial Biotherapeutics Autism Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 AXIM BIOTECH IN AUTISM PIPELINE DETAILS

- 8.1 Axim Biotech In Business Profile
- 8.2 Axim Biotech In Autism Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 BANTAM PHARMACEUTICAL LLC AUTISM PIPELINE DETAILS

- 9.1 Bantam Pharmaceutical LLC Business Profile
- 9.2 Bantam Pharmaceutical LLC Autism Drug Details
- 9.3 Drug Snapshot

- 9.3.1 Originator
- 9.3.2 Collaborator/Co-Developer
- 9.3.3 Route of Administration
- 9.3.4 Orphan Drug/Fast Track/Special Designation
- 9.3.5 Geography
- 9.3.6 Type of Molecular Entity
- 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 BIOHEALTHONOMICS INC AUTISM PIPELINE DETAILS

- 10.1 BioHealthonomics Inc Business Profile
- 10.2 BioHealthonomics Inc Autism Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 BRAINSTORM CELL THERAPEUTICS INC AUTISM PIPELINE DETAILS

- 11.1 BrainStorm Cell Therapeutics Inc Business Profile
- 11.2 BrainStorm Cell Therapeutics Inc Autism Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography

- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 CANNABIS SCIENCE INC AUTISM PIPELINE DETAILS

- 12.1 cannabis science Inc Business Profile
- 12.2 cannabis science Inc Autism Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 CENNERV PHARMA (S) PTE LTD AUTISM PIPELINE DETAILS

- 13.1 Cennerv Pharma (S) Pte Ltd Business Profile
- 13.2 Cennerv Pharma (S) Pte Ltd Autism Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14 CORONIS NEUROSCIENCES LTD AUTISM PIPELINE DETAILS

- 14.1 Coronis NeuroSciences Ltd Business Profile
- 14.2 Coronis NeuroSciences Ltd Autism Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 CUREMARK LLC AUTISM PIPELINE DETAILS

- 15.1 Curemark LLC Business Profile
- 15.2 Curemark LLC Autism Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 CYTOCOM INC AUTISM PIPELINE DETAILS

- 16.1 Cytocom Inc Business Profile

16.2 Cytocom Inc Autism Drug Details

16.3 Drug Snapshot

16.3.1 Originator

16.3.2 Collaborator/Co-Developer

16.3.3 Route of Administration

16.3.4 Orphan Drug/Fast Track/Special Designation

16.3.5 Geography

16.3.6 Type of Molecular Entity

16.3.7 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

17 EVGEN PHARMA PLC AUTISM PIPELINE DETAILS

17.1 Evgen Pharma Plc Business Profile

17.2 Evgen Pharma Plc Autism Drug Details

17.3 Drug Snapshot

17.3.1 Originator

17.3.2 Collaborator/Co-Developer

17.3.3 Route of Administration

17.3.4 Orphan Drug/Fast Track/Special Designation

17.3.5 Geography

17.3.6 Type of Molecular Entity

17.3.7 Current Status

17.4 Drug Overview

17.5 Drug Mechanism of Action

17.6 Clinical/Pre-clinical Trial Details

17.7 Latest Drug Developments

18 F. HOFFMANN-LA ROCHE LTD AUTISM PIPELINE DETAILS

18.1 F. Hoffmann-La Roche Ltd Business Profile

18.2 F. Hoffmann-La Roche Ltd Autism Drug Details

18.3 Drug Snapshot

18.3.1 Originator

18.3.2 Collaborator/Co-Developer

18.3.3 Route of Administration

- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 GW PHARMACEUTICALS PLC AUTISM PIPELINE DETAILS

- 19.1 GW Pharmaceuticals Plc Business Profile
- 19.2 GW Pharmaceuticals Plc Autism Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 HEPTARES THERAPEUTICS LTD AUTISM PIPELINE DETAILS

- 20.1 Heptares Therapeutics Ltd Business Profile
- 20.2 Heptares Therapeutics Ltd Autism Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status
- 20.4 Drug Overview

- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 IMMURON LTD AUTISM PIPELINE DETAILS

- 21.1 Immuron Ltd Business Profile
- 21.2 Immuron Ltd Autism Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 INTRA-CELLULAR THERAPIES INC AUTISM PIPELINE DETAILS

- 22.1 Intra-Cellular Therapies Inc Business Profile
- 22.2 Intra-Cellular Therapies Inc Autism Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity
 - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 MEDDAY SA AUTISM PIPELINE DETAILS

- 23.1 MedDay SA Business Profile
- 23.2 MedDay SA Autism Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 NEUROCHLORE AUTISM PIPELINE DETAILS

- 24.1 Neurochlore Business Profile
- 24.2 Neurochlore Autism Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25 OMEROS CORPORATION AUTISM PIPELINE DETAILS

- 25.1 Omeros Corporation Business Profile
- 25.2 Omeros Corporation Autism Drug Details
- 25.3 Drug Snapshot
 - 25.3.1 Originator

- 25.3.2 Collaborator/Co-Developer
- 25.3.3 Route of Administration
- 25.3.4 Orphan Drug/Fast Track/Special Designation
- 25.3.5 Geography
- 25.3.6 Type of Molecular Entity
- 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26 OPTINOSE US INC AUTISM PIPELINE DETAILS

- 26.1 OptiNose US Inc Business Profile
- 26.2 OptiNose US Inc Autism Drug Details
- 26.3 Drug Snapshot
 - 26.3.1 Originator
 - 26.3.2 Collaborator/Co-Developer
 - 26.3.3 Route of Administration
 - 26.3.4 Orphan Drug/Fast Track/Special Designation
 - 26.3.5 Geography
 - 26.3.6 Type of Molecular Entity
 - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27 OVENSA INC AUTISM PIPELINE DETAILS

- 27.1 Ovensa Inc Business Profile
- 27.2 Ovensa Inc Autism Drug Details
- 27.3 Drug Snapshot
 - 27.3.1 Originator
 - 27.3.2 Collaborator/Co-Developer
 - 27.3.3 Route of Administration
 - 27.3.4 Orphan Drug/Fast Track/Special Designation
 - 27.3.5 Geography
 - 27.3.6 Type of Molecular Entity

- 27.3.7 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28 PANORAMA RESEARCH INC AUTISM PIPELINE DETAILS

- 28.1 Panorama Research Inc Business Profile
- 28.2 Panorama Research Inc Autism Drug Details
- 28.3 Drug Snapshot
 - 28.3.1 Originator
 - 28.3.2 Collaborator/Co-Developer
 - 28.3.3 Route of Administration
 - 28.3.4 Orphan Drug/Fast Track/Special Designation
 - 28.3.5 Geography
 - 28.3.6 Type of Molecular Entity
 - 28.3.7 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

29 PARK ACTIVE MOLECULES AUTISM PIPELINE DETAILS

- 29.1 Park Active Molecules Business Profile
- 29.2 Park Active Molecules Autism Drug Details
- 29.3 Drug Snapshot
 - 29.3.1 Originator
 - 29.3.2 Collaborator/Co-Developer
 - 29.3.3 Route of Administration
 - 29.3.4 Orphan Drug/Fast Track/Special Designation
 - 29.3.5 Geography
 - 29.3.6 Type of Molecular Entity
 - 29.3.7 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action
- 29.6 Clinical/Pre-clinical Trial Details
- 29.7 Latest Drug Developments

30 RESPIRERX PHARMACEUTICALS INC AUTISM PIPELINE DETAILS

- 30.1 RespireRx Pharmaceuticals Inc Business Profile
- 30.2 RespireRx Pharmaceuticals Inc Autism Drug Details
- 30.3 Drug Snapshot
 - 30.3.1 Originator
 - 30.3.2 Collaborator/Co-Developer
 - 30.3.3 Route of Administration
 - 30.3.4 Orphan Drug/Fast Track/Special Designation
 - 30.3.5 Geography
 - 30.3.6 Type of Molecular Entity
 - 30.3.7 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31 REVIVA PHARMACEUTICALS INC AUTISM PIPELINE DETAILS

- 31.1 Reviva Pharmaceuticals Inc Business Profile
- 31.2 Reviva Pharmaceuticals Inc Autism Drug Details
- 31.3 Drug Snapshot
 - 31.3.1 Originator
 - 31.3.2 Collaborator/Co-Developer
 - 31.3.3 Route of Administration
 - 31.3.4 Orphan Drug/Fast Track/Special Designation
 - 31.3.5 Geography
 - 31.3.6 Type of Molecular Entity
 - 31.3.7 Current Status
- 31.4 Drug Overview
- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

32 ROGCON U.R. INC AUTISM PIPELINE DETAILS

- 32.1 RogCon U.R. Inc Business Profile
- 32.2 RogCon U.R. Inc Autism Drug Details

- 32.3 Drug Snapshot
 - 32.3.1 Originator
 - 32.3.2 Collaborator/Co-Developer
 - 32.3.3 Route of Administration
 - 32.3.4 Orphan Drug/Fast Track/Special Designation
 - 32.3.5 Geography
 - 32.3.6 Type of Molecular Entity
 - 32.3.7 Current Status
- 32.4 Drug Overview
- 32.5 Drug Mechanism of Action
- 32.6 Clinical/Pre-clinical Trial Details
- 32.7 Latest Drug Developments

33 RUGEN THERAPEUTICS R&D (SHANGHAI) CO LTD AUTISM PIPELINE DETAILS

- 33.1 Rugen Therapeutics R&D (Shanghai) Co Ltd Business Profile
- 33.2 Rugen Therapeutics R&D (Shanghai) Co Ltd Autism Drug Details
- 33.3 Drug Snapshot
 - 33.3.1 Originator
 - 33.3.2 Collaborator/Co-Developer
 - 33.3.3 Route of Administration
 - 33.3.4 Orphan Drug/Fast Track/Special Designation
 - 33.3.5 Geography
 - 33.3.6 Type of Molecular Entity
 - 33.3.7 Current Status
- 33.4 Drug Overview
- 33.5 Drug Mechanism of Action
- 33.6 Clinical/Pre-clinical Trial Details
- 33.7 Latest Drug Developments

34 SECOND GENOME INC AUTISM PIPELINE DETAILS

- 34.1 Second Genome Inc Business Profile
- 34.2 Second Genome Inc Autism Drug Details
- 34.3 Drug Snapshot
 - 34.3.1 Originator
 - 34.3.2 Collaborator/Co-Developer
 - 34.3.3 Route of Administration

- 34.3.4 Orphan Drug/Fast Track/Special Designation
- 34.3.5 Geography
- 34.3.6 Type of Molecular Entity
- 34.3.7 Current Status
- 34.4 Drug Overview
- 34.5 Drug Mechanism of Action
- 34.6 Clinical/Pre-clinical Trial Details
- 34.7 Latest Drug Developments

35 SEROPEUTICS LLC AUTISM PIPELINE DETAILS

- 35.1 Seropeutics LLC Business Profile
- 35.2 Seropeutics LLC Autism Drug Details
- 35.3 Drug Snapshot
 - 35.3.1 Originator
 - 35.3.2 Collaborator/Co-Developer
 - 35.3.3 Route of Administration
 - 35.3.4 Orphan Drug/Fast Track/Special Designation
 - 35.3.5 Geography
 - 35.3.6 Type of Molecular Entity
 - 35.3.7 Current Status
- 35.4 Drug Overview
- 35.5 Drug Mechanism of Action
- 35.6 Clinical/Pre-clinical Trial Details
- 35.7 Latest Drug Developments

36 STEM CELL MEDICINE LTD AUTISM PIPELINE DETAILS

- 36.1 Stem Cell Medicine Ltd Business Profile
- 36.2 Stem Cell Medicine Ltd Autism Drug Details
- 36.3 Drug Snapshot
 - 36.3.1 Originator
 - 36.3.2 Collaborator/Co-Developer
 - 36.3.3 Route of Administration
 - 36.3.4 Orphan Drug/Fast Track/Special Designation
 - 36.3.5 Geography
 - 36.3.6 Type of Molecular Entity
 - 36.3.7 Current Status
- 36.4 Drug Overview

- 36.5 Drug Mechanism of Action
- 36.6 Clinical/Pre-clinical Trial Details
- 36.7 Latest Drug Developments

37 SUMITOMO CHEMICAL CO LTD AUTISM PIPELINE DETAILS

- 37.1 Sumitomo Chemical Co Ltd Business Profile
- 37.2 Sumitomo Chemical Co Ltd Autism Drug Details
- 37.3 Drug Snapshot
 - 37.3.1 Originator
 - 37.3.2 Collaborator/Co-Developer
 - 37.3.3 Route of Administration
 - 37.3.4 Orphan Drug/Fast Track/Special Designation
 - 37.3.5 Geography
 - 37.3.6 Type of Molecular Entity
 - 37.3.7 Current Status
- 37.4 Drug Overview
- 37.5 Drug Mechanism of Action
- 37.6 Clinical/Pre-clinical Trial Details
- 37.7 Latest Drug Developments

38 SYSTEM1 BIOSCIENCES INC AUTISM PIPELINE DETAILS

- 38.1 System1 Biosciences Inc Business Profile
- 38.2 System1 Biosciences Inc Autism Drug Details
- 38.3 Drug Snapshot
 - 38.3.1 Originator
 - 38.3.2 Collaborator/Co-Developer
 - 38.3.3 Route of Administration
 - 38.3.4 Orphan Drug/Fast Track/Special Designation
 - 38.3.5 Geography
 - 38.3.6 Type of Molecular Entity
 - 38.3.7 Current Status
- 38.4 Drug Overview
- 38.5 Drug Mechanism of Action
- 38.6 Clinical/Pre-clinical Trial Details
- 38.7 Latest Drug Developments

39 TRANSLATIONAL BIOSCIENCES AUTISM PIPELINE DETAILS

- 39.1 Translational Biosciences Business Profile
- 39.2 Translational Biosciences Autism Drug Details
- 39.3 Drug Snapshot
 - 39.3.1 Originator
 - 39.3.2 Collaborator/Co-Developer
 - 39.3.3 Route of Administration
 - 39.3.4 Orphan Drug/Fast Track/Special Designation
 - 39.3.5 Geography
 - 39.3.6 Type of Molecular Entity
 - 39.3.7 Current Status
- 39.4 Drug Overview
- 39.5 Drug Mechanism of Action
- 39.6 Clinical/Pre-clinical Trial Details
- 39.7 Latest Drug Developments

40 YAMO PHARMACEUTICALS LLC AUTISM PIPELINE DETAILS

- 40.1 Yamo Pharmaceuticals LLC Business Profile
- 40.2 Yamo Pharmaceuticals LLC Autism Drug Details
- 40.3 Drug Snapshot
 - 40.3.1 Originator
 - 40.3.2 Collaborator/Co-Developer
 - 40.3.3 Route of Administration
 - 40.3.4 Orphan Drug/Fast Track/Special Designation
 - 40.3.5 Geography
 - 40.3.6 Type of Molecular Entity
 - 40.3.7 Current Status
- 40.4 Drug Overview
- 40.5 Drug Mechanism of Action
- 40.6 Clinical/Pre-clinical Trial Details
- 40.7 Latest Drug Developments

41 ZELDA THERAPEUTICS PTY LTD AUTISM PIPELINE DETAILS

- 41.1 Zelda Therapeutics Pty Ltd Business Profile
- 41.2 Zelda Therapeutics Pty Ltd Autism Drug Details
- 41.3 Drug Snapshot
 - 41.3.1 Originator

- 41.3.2 Collaborator/Co-Developer
- 41.3.3 Route of Administration
- 41.3.4 Orphan Drug/Fast Track/Special Designation
- 41.3.5 Geography
- 41.3.6 Type of Molecular Entity
- 41.3.7 Current Status
- 41.4 Drug Overview
- 41.5 Drug Mechanism of Action
- 41.6 Clinical/Pre-clinical Trial Details
- 41.7 Latest Drug Developments

42. LATEST AUTISM DRUG PIPELINE DEVELOPMENTS, 2019

43. APPENDIX

- 43.1 About Us
- 43.2 Sources and Methodology
- 43.3 Contact Information

I would like to order

Product name: 2019 Future of Autism R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/29B3981FE59EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/29B3981FE59EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

